The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with ...

The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...

New findings from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM), published in ...

Prostate cancer begins in the prostate, a small gland located just below the bladder, present only in people assigned male at birth (AMAB). This gland is in charge of producing seminal fluid, and it ...

Oric Pharmaceuticals has picked the phase 3 dose for its prostate cancer prospect, barreling into the pivotal program while ...

Read more about how low testosterone levels are linked to ‘extreme’ disease progression in patients with prostate cancer ...

Researchers at Texas A&M Health have identified a molecular mechanism that increases cholesterol levels inside prostate cancer cells—an important process that may help explain how some tumors progress ...

Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all ...

Low testosterone may raise the risk of aggressive prostate cancer progression in men under monitoring, a study finds.

Based on the efficacy and safety data, Oric will advance the 400mg therapy to Phase III trials, with more treatment-emergent ...